Wockhardt activates Zaynich push, eyes global licensing deals
Wockhardt
is working on ambitious plans for
Zaynich
, a combination of zidebactam and cefepime that was found to be effective during
clinical trials
to fight
superbugs
or bacterial infections that show resistance to a range of existing antibiotic treatments.
The drug maker has hired merchant bankers to identify possible out-licensing deals for the novel product, chairman Habil Khorakiwala told ET in an exclusive interview.
Wockhardt
in March sought regulatory approval for Zaynich in India and expects its commercial launch in the first half of '26. In the US, it plans to file for regulatory clearance in August.'We will get into the US market by the end of FY26 or latest by the second half of 2026 and Europe will be a year later,' Khorakiwala said.
Zaynich is seen as a game-changing drug against drug-resistant gram-negative pathogens.
Play Video
Pause
Skip Backward
Skip Forward
Unmute
Current Time
0:00
/
Duration
0:00
Loaded
:
0%
0:00
Stream Type
LIVE
Seek to live, currently behind live
LIVE
Remaining Time
-
0:00
1x
Playback Rate
Chapters
Chapters
Descriptions
descriptions off
, selected
Captions
captions settings
, opens captions settings dialog
captions off
, selected
Audio Track
default
, selected
Picture-in-Picture
Fullscreen
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Text
Color
White
Black
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Opaque
Semi-Transparent
Text Background
Color
Black
White
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Opaque
Semi-Transparent
Transparent
Caption Area Background
Color
Black
White
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Transparent
Semi-Transparent
Opaque
Font Size
50%
75%
100%
125%
150%
175%
200%
300%
400%
Text Edge Style
None
Raised
Depressed
Uniform
Drop shadow
Font Family
Proportional Sans-Serif
Monospace Sans-Serif
Proportional Serif
Monospace Serif
Casual
Script
Small Caps
Reset
restore all settings to the default values
Done
Close Modal Dialog
End of dialog window.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
2025년 가장 여유 넘치는 농장 게임. 설치 없음
Taonga: 아일랜드 팜
플레이하기
Undo
These pathogens are difficult to kill. Zaynich is estimated to have a
market opportunity
of about $9 billion. Around a million people die due to multidrug resistance in India every year, while worldwide, the number is 5 million, Khorakiwala said. Currently there are very few effective treatments available for these infections.
Mumbai-based Wockhardt completed the Phase-3 clinical trials for Zaynich earlier this year. In January it announced that the drug demonstrated more than 97% clinical efficacy in treating serious infections of bacteria resistant to carbapenem antibiotics, which are often used as a last resort to treat severe infections.
Live Events
The company is prepared to go solo to market Zaynich in India, the US and other markets if the licensing proposals do not meet its expectations on valuation, Khorakiwala said without revealing the valuation he is looking for.
'We will evaluate how to go about and take an appropriate call, so we are keeping two options fully alive,' Khorakiwala said. 'One option is licensing out, the other is in some markets like in India we are doing ourselves,' he said. 'The US is another market where we are thinking of the possibility (of marketing on its own); you don't need too much marketing cost and you have talent available.'
Wockhardt also plans to fully outsource manufacturing for the Western markets to eliminate issues related to the US Food and Drug Administration, and channel its focus on the clinical and research part.
'For manufacturing, plenty of options are available in Europe and the US, so I am not getting into FDA-related manufacturing problems,' said Khorakiwala. 'Zaynich — we are manufacturing everything in Europe.' It will adopt the same strategy to outsource most of the manufacturing for all its other new products.
The company had in the past faced some issues with the US FDA over alleged violations of good manufacturing practices. 'That (FDA-elated manufacturing problems) was our weakness, and I am eliminating that completely from my western markets to only focus on the clinical and research part,' he said.
COMPANY TURNAROUND
Wockhardt has seen a remarkable turnaround in its stock price in the past year and a half with renewed confidence from investors, with developments on Zaynich being among the key drivers. Its stock price more than doubled in the last 12 months and increased over three-and-a-half times since January 2024. The shares closed at `1,713.20, up 4.5%, on BSE Monday. 'We have revisited what are the strengths and what are the opportunities — one obviously is our new drug discovery — in India and worldwide,' said Khorakiwala.
He also stressed on the company's focus on biologics as another key growth driver.
'Within biologics we will stay in insulin and GLP1; we are not going to touch the rest of the biologics like monoclonal antibodies and others. Because we feel it is important to be focused,' he said.
Wockhardt does not see itself as a generic company, he said. 'In fact, in the US we are exiting generics … we will be focused on the biological area and NCE (new chemical entities) and strictly on antibiotics,' he said.
The chairman said his research pipeline has a range of antibiotics under development, including early-stage work on an oral version of Zaynich.
PRICING STRATEGY
Khorakiwala said the treatment cost with most new products including antimicrobials launched in the last 10 years in the US has been in the range of $10,000-15,000 per treatment. Zaynich will also hover in that range in the US but in India, the price will be significantly lower, he said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
13 minutes ago
- Business Standard
Tesco to set up distribution hub, create 15,000 jobs: K'taka Industries Min
UK-based retail giant Tesco plans to set up a new distribution centre in Karnataka, creating 15,000 additional jobs, Large and Medium Industries Minister M B Patil said on Wednesday. UK engineering major Rolls-Royce is also exploring fresh investments in the state, he said, adding that the government would expedite all necessary processes to facilitate the company's plans, his office said in a release. Patil made the announcement while addressing a reception hosted on Tuesday by the British Deputy High Commission to mark the signing of the IndiaUnited Kingdom Free Trade Agreement (FTA). The pact is projected to boost bilateral trade by about Euro 25 billion annually and help double trade volumes to nearly Euro 90 billion by 2030. The FTA would pave the way for duty-free access for 99 per cent of India's exports to the UK and 90 per cent of UK exports to India. This would mean more affordable products, greater market access for businesses, and a surge in commerce benefiting consumers and industries in both countries, he said. Patil noted that leading British firms such as Rolls-Royce, BAE Systems, Tesco, ARM, HSBC, and Aviva already have a strong presence in Bengaluru and across Karnataka, collectively employing nearly 30,000 people in the state. He said the FTA would enable UK companies to scale up investments in Karnataka and urged them to leverage the state's technology capabilities, infrastructure, and industry-friendly policies. The government will respond proactively to those keen on investing, he assured. According to the minister's office, the event was attended by Harjinder Singh, UK Trade Commissioner; Chandru Iyer, British Deputy High Commissioner; and other dignitaries.
&w=3840&q=100)
Business Standard
13 minutes ago
- Business Standard
Kalpataru posts Rs 49 crore loss in Q1 FY26 despite strong pre-sales
Mumbai-based real estate developer Kalpataru reported a widening of losses to Rs 49.43 crore in the first quarter of FY26, compared with Rs 0.69 crore in Q1 FY25. Revenue from operations stood at Rs 443.2 crore, down 16.45 per cent year-on-year (Y-o-Y), while total expenses fell 5.18 per cent Y-o-Y to Rs 512.23 crore. The company follows the project completion method (PCM) for recognising revenue from projects launched after April 2022. Under this method, revenue is recorded only upon receipt of the occupation certificate (OC), whereas expenses such as marketing and corporate overheads are booked in the same quarter they are incurred. As of Q1 FY26, the majority of recognised revenue came from projects under PCM. Of its 24 ongoing projects, Kalpataru applies PCM to 13; however, costs associated with these projects are fully charged to the profit and loss account during the reporting period. Pre-sales rose 83 per cent Y-o-Y to Rs 1,249 crore, while collections increased 37 per cent YoY to Rs 1,147 crore. However, the area sold fell 9 per cent Y-o-Y to 0.56 million square feet. Average sales realisation during the quarter surged 101 per cent Y-o-Y to Rs 22,476 per square foot. The company has guided pre-sales of Rs 7,000 crore for FY26, up from Rs 4,531 crore in FY25. It is targeting collections of Rs 5,700 crore, compared with Rs 3,659 crore in the previous financial year. Debt reduction focus Net debt as of June 30, 2025, stood at Rs 7,939 crore. The net debt-to-equity ratio improved to 2.0x from 3.8x as of March 31, 2025. Kalpataru aims to reduce its debt to Rs 7,300 crore by the end of FY26. 'The company has utilised Rs 1,192.5 crore from IPO proceeds towards debt repayment, in line with the objects of the issue, and remains committed to further strengthening the balance sheet through continued debt reduction efforts,' said Parag Munot, Managing Director, Kalpataru. On a sequential basis, revenue declined 26 per cent. The company had posted a profit of Rs 14.05 crore in Q4 FY25, compared with a loss in the current quarter. Kalpataru shares closed at Rs 406.30 on the BSE on Tuesday.
Deccan Herald
13 minutes ago
- Deccan Herald
Optiemus partners with US-based Corning to produce tempered glass in India
New Delhi: Optiemus Infracom in partnership with US-based Corning Inc on Wednesday announced that it will manufacture tempered glass screen protectors for smartphones in India. Noida-based firm claimed that it is the first company in India to locally produce advanced-grade screen protectors featuring Corning glass technology.'We are committed to establishing India as a global hub for high-value mobile accessories," said Ashok Kumar Gupta, Chairman, Optiemus Infracom company will produce premium tempered glass screen protectors under the brand 'RhinoTech'. It targets around Rs 2,000 crore revenue from the tempered glass business by March 2027. Majority of the tempered glass used for protecting smartphone screens in India is imported from informed that RhinoTech screen protectors will be manufactured at Optiemus' facility in Noida, Uttar Pradesh. 'Our state-of-the-art manufacturing plant enables RhinoTech to reliably meet the growing demand of Indian consumers while maintaining consistent quality and widespread availability across the nation,' Optiemus said in a screen protectors will initially be available for the premium smartphone category. The company plans to expand its offerings to cater to other categories, including the economy smartphone category, in the coming RhinoTech products will be available in the Indian market starting end of September 2025 through the official RhinoTech website and authorised dealers/retail chains in select cities.'We are excited to work with Optiemus to help offer Indian consumers the choice of a screen protector that is marked as Engineered by Corning. We believe that this development will support the country's growing need for providing screen protectors for the mobile consumer electronics industry,' said Sudhir Pillai, Managing Director, Corning tempered glass screen protectors market is valued at around Rs 20,000 crore. Over 90% of it is met through low-cost imports, leading to inconsistent quality and an unorganised address this, the government last month introduced the Indian standard for 'Chemically Tempered Glass Screen Protectors' via the Bureau of Indian Standards (BIS) on 28 July 2025. Gupta said all RhinoTech screen protectors will be as per the BIS norms.
